{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:13:17Z","timestamp":1784729597287,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The 5\u2010hydroxytryptamine type\u20104 receptor agonist felcisetrag (TAK\u2010954) is being investigated for improving gastrointestinal motility in postoperative gastrointestinal dysfunction. Polypharmacy often occurs in this setting, and as in vitro data indicate, felcisetrag is primarily metabolized by cytochrome P450 (CYP) 3A4, its CYP3A4\u2010mediated drug\u2010drug interaction potential requires consideration. This phase\u00a01, fixed\u2010sequence, open\u2010label, crossover trial (ClinicalTrials.gov identifier NCT03173170) investigated the effect of itraconazole, a potent CYP3A4 inhibitor, on felcisetrag pharmacokinetics in healthy adults. Over 2 study periods (period 1, 6 days; period 2, 9 days), participants received a single felcisetrag 0.2\u2010mg intravenous dose (day 1, period 1; and day 4, period 2), and once\u2010daily oral itraconazole 200\u2010mg doses (days 1\u20108, period 2). For felcisetrag alone, felcisetrag total systemic exposure was lower than with itraconazole coadministration. The geometric mean ratio for area under the plasma concentration\u2013time curve from time 0 to infinity of felcisetrag plus itraconazole: felcisetrag alone was 1.49 (90% confidence interval, 1.39\u20101.60). Peak exposure was similar between regimens (geometric mean ratio, 1.06; 90% confidence interval, 0.96\u20101.18), and both treatments were well tolerated. These data suggest limited CYP3A4\u2010mediated drug\u2010drug interaction inhibition for felcisetrag.<\/jats:p>","DOI":"10.1002\/cpdd.1046","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T09:55:04Z","timestamp":1641462904000},"page":"142-149","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the Pharmacokinetics of Felcisetrag (TAK\u2010954), a 5\u2010HT<sub>4<\/sub> Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor"],"prefix":"10.1002","volume":"11","author":[{"given":"Chunlin","family":"Chen","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"},{"name":"Bayer Pharmaceuticals  Whippany New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Almansa","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"},{"name":"Ironwood Pharmaceuticals  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rosario","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"},{"name":"Syros Pharmaceuticals Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cwik","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Balani","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Lock","sequence":"additional","affiliation":[{"name":"Aucuba Sciences Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02235480"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.SLA.0000081094.66659.c3"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-016-1485-1"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002742"},{"issue":"1","key":"e_1_2_10_6_1","first-page":"44","article-title":"Alvimopan (Entereg) for the management of postoperative ileus in patients undergoing bowel resection","volume":"35","author":"Kraft M","year":"2010","journal-title":"P T"},{"key":"e_1_2_10_7_1","article-title":"Intermediate acting non\u2010depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study","author":"Grosse\u2010Sundrup M","year":"2012","journal-title":"BMJ"},{"issue":"8","key":"e_1_2_10_8_1","article-title":"Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults","author":"Hristovska AM","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.76a.09051"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000253410.36492.E9"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936114527744"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2011.00025"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05011.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.693"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviscsurg.2016.08.010"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-013-3158-2"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-017-2789-5"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1732"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.711500"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16304"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.079"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00145.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.160-165.2002"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12668"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:18:48Z","timestamp":1692663528000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/cpdd.1046"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1046","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"2019-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}